{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:06:04Z","timestamp":1792739164854,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CD40 agonists bind the CD40 molecule on antigen-presenting cells and activate them to prime tumor-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses. Here, we study the antitumor activity and mechanism of action of a nonreplicating adenovirus encoding a chimeric, membrane-bound CD40 ligand (ISF35). Intratumoral administration of ISF35 in subcutaneous B16 melanomas generates tumor-specific, CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells that express PD-1 and suppress tumor growth.\u00a0Combination therapy of ISF35 with systemic anti-PD-1 generates greater antitumor activity than each respective monotherapy. Triple combination of ISF35, anti-PD-1, and anti-CTLA-4 results in complete eradication of injected and noninjected subcutaneous tumors, as well as melanoma tumors in the brain. Therapeutic efficacy is associated with increases in the systemic level of tumor-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, and an increased ratio of intratumoral CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells to CD4\n                    <jats:sup>+<\/jats:sup>\n                    Tregs. These results provide a proof of concept of systemic antitumor activity after intratumoral CD40 triggering with ISF35 in combination with checkpoint blockade for multifocal cancer, including the brain.\n                  <\/jats:p>","DOI":"10.1038\/s41467-017-01572-7","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T07:25:07Z","timestamp":1510039507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain"],"prefix":"10.1038","volume":"8","author":[{"given":"Manisha","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Vianden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Cantwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-7862","authenticated-orcid":false,"given":"Hiep","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvin R.","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Faak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yared","family":"Hailemichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M. E.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddalak","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Tweardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem W.","family":"Overwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,13]]},"reference":[{"key":"1572_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1586\/ern.12.111","volume":"12","author":"E Fonkem","year":"2012","unstructured":"Fonkem, E. et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert. Rev. Neurother. \n                           12, 1207\u20131215 (2012).","journal-title":"Expert. Rev. Neurother."},{"key":"1572_CR2","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. \n                           372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1572_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. \n                           10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"1572_CR4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1172\/JCI64859","volume":"123","author":"A Marabelle","year":"2013","unstructured":"Marabelle, A. et al. Depleting tumor\u2010specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. \n                           123, 2447\u20132463 (2013).","journal-title":"J. Clin. Invest."},{"key":"1572_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. \n                           6, 226ra32 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.4049\/jimmunol.1401160","volume":"193","author":"M Singh","year":"2014","unstructured":"Singh, M. et al. Effective innate and adaptive antimelanoma immunity through localized TLR7\/8 activation. J. Immunol. \n                           193, 4722\u20134731 (2014).","journal-title":"J. Immunol."},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/10503","volume":"5","author":"EM Sotomayor","year":"1999","unstructured":"Sotomayor, E. M. et al. Conversion of tumor\u2010specific CD4+T\u2010cell tolerance to T\u2010cell priming through in vivo ligation of CD40. Nat. Med. \n                           5, 780\u2013787 (1999).","journal-title":"Nat. Med."},{"key":"1572_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","volume":"25","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP\u2010870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. \n                           25, 876\u2013883 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1572_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. \n                           19, 1035\u20131043 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/hum.2014.015","volume":"26","author":"M Urquiza","year":"2015","unstructured":"Urquiza, M. et al. Intratumoral injection of Ad\u2010ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum. Gene. Ther. \n                           26, 14\u201325 (2015).","journal-title":"Hum. Gene. Ther."},{"key":"1572_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/cgt.2012.6","volume":"19","author":"J Melo\u2010Cardenas","year":"2012","unstructured":"Melo\u2010Cardenas, J., Urquiza, M., Kipps, T. J. & Castro, J. E. Intratumoral delivery of CD154 homolog (Ad\u2010ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Cancer Gene. Ther. \n                           19, 336\u2013344 (2012).","journal-title":"Cancer Gene. Ther."},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/0008-5472.CAN-11-3368","volume":"72","author":"JE Castro","year":"2012","unstructured":"Castro, J. E. et al. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. \n                           72, 2937\u20132948 (2012).","journal-title":"Cancer Res."},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ng.356","volume":"41","author":"D Dankort","year":"2009","unstructured":"Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. \n                           41, 544\u2013552 (2009).","journal-title":"Nat. Genet."},{"key":"1572_CR14","first-page":"7920","volume":"61","author":"MH Kershaw","year":"2001","unstructured":"Kershaw, M. H. et al. Immunization against endogenous retroviral tumor\u2010associated antigens. Cancer. Res. \n                           61, 7920\u20137924 (2001).","journal-title":"Cancer. Res."},{"key":"1572_CR15","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.4049\/jimmunol.1000749","volume":"185","author":"Y Zhu","year":"2010","unstructured":"Zhu, Y. et al. T\u2010bet and eomesodermin are required for T cell\u2010mediated antitumor immune responses. J. Immunol. \n                           185, 3174\u20133183 (2010).","journal-title":"J. Immunol."},{"key":"1572_CR16","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1073\/pnas.96.6.2982","volume":"96","author":"WW Overwijk","year":"1999","unstructured":"Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a \u201cself\u201d antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl Acad. Sci. USA \n                           96, 2982\u20132987 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1572_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.apsb.2013.12.001","volume":"4","author":"CP Wu","year":"2014","unstructured":"Wu, C. P. & Ambudkar, S. V. The pharmacological impact of ATP\u2010binding cassette drug transporters on vemurafenib\u2010based therapy. Acta Pharm. Sin. B \n                           4, 105\u2013111 (2014).","journal-title":"Acta Pharm. Sin. B"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14728214.2012.679929","volume":"17","author":"DA Wainwright","year":"2012","unstructured":"Wainwright, D. A. et al. Recent developments on immunotherapy for brain cancer. Expert Opin. Emerg. Drugs \n                           17, 181\u2013202 (2012).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/CJI.0b013e31824e7f43","volume":"35","author":"C Liu","year":"2012","unstructured":"Liu, C. et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J. Immunother. \n                           35, 276\u2013282 (2012).","journal-title":"J. Immunother."},{"key":"1572_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/08830185.2012.702511","volume":"31","author":"RS Kornbluth","year":"2012","unstructured":"Kornbluth, R. S. & Bot, A. In this issue: harnessing immunity against difficult targets, through the CD40\u2010CD40L pathway. Int. Rev. Immunol. \n                           31, 243\u2013245 (2012).","journal-title":"Int. Rev. Immunol."},{"key":"1572_CR21","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.4049\/jimmunol.171.12.6478","volume":"171","author":"A Clatza","year":"2003","unstructured":"Clatza, A., Bonifaz, L. C., Vignali, D. A. & Moreno, J. CD40\u2010induced aggregation of MHC class II and CD80 on the cell surface leads to an early enhancement in antigen presentation. J. Immunol. \n                           171, 6478\u20136487 (2003).","journal-title":"J. Immunol."},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","volume":"15","author":"KT Byrne","year":"2016","unstructured":"Byrne, K. T. & Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. \n                           15, 2719\u20132732 (2016).","journal-title":"Cell Rep."},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/526622a","volume":"526","author":"H Ledford","year":"2015","unstructured":"Ledford, H. Cancer\u2010fighting viruses win approval. Nature \n                           526, 622\u2013623 (2015).","journal-title":"Nature"},{"key":"1572_CR24","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer, N. N. et al. Phase II clinical trial of a granulocyte\u2010macrophage colony\u2010stimulating factor\u2010encoding, second\u2010generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. \n                           27, 5763\u20135771 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1572_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti\u2010tumour properties. Gene. Ther. \n                           10, 292\u2013303 (2003).","journal-title":"Gene. Ther."},{"key":"1572_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B., Puzanov, I. & Kelley, M. C. Talimogene laherparepvec (T\u2010VEC) for the treatment of advanced melanoma. Immunotherapy \n                           7, 611\u2013619 (2015).","journal-title":"Immunotherapy"},{"key":"1572_CR27","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc\u2010dependent depletion of tumor\u2010infiltrating regulatory T cells co\u2010 defines the efficacy of anti\u2010CTLA\u20104 therapy against melanoma. J. Exp. Med. \n                           210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"1572_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.intimp.2016.03.009","volume":"34","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. CD4+CD25+regulatory T cells in tumor immunity. Int. Immunopharmacol. \n                           34, 244\u2013249 (2016).","journal-title":"Int. Immunopharmacol."},{"key":"1572_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/CJI.0b013e3181ee73a7","volume":"33","author":"A Kalbasi","year":"2010","unstructured":"Kalbasi, A. et al. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti\u2010CD40 antibody CP\u2010870,893. J. Immunother. \n                           33, 810\u2013816 (2010).","journal-title":"J. Immunother."},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(SICI)1096-9896(199905)188:1<38::AID-PATH315>3.0.CO;2-B","volume":"188","author":"PW Cooke","year":"1999","unstructured":"Cooke, P. W. et al. CD40 expression in bladder cancer. J. Pathol. \n                           188, 38\u201343 (1999).","journal-title":"J. Pathol."},{"key":"1572_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/mp.55.2.110","volume":"55","author":"NJ Gallagher","year":"2002","unstructured":"Gallagher, N. J. et al. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol. Pathol. \n                           55, 110\u2013120 (2002).","journal-title":"Mol. Pathol."},{"key":"1572_CR32","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","volume":"16","author":"T Ajithkumar","year":"2015","unstructured":"Ajithkumar, T. et al. Evolving treatment options for melanoma brain metastases. Lancet. Oncol. \n                           16, e486\u2013e497 (2015).","journal-title":"Lancet. Oncol."},{"key":"1572_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","volume":"1","author":"S Goyal","year":"2015","unstructured":"Goyal, S. et al. Clinical management of multiple melanoma brain metastases: a systematic review. JAMA Oncol. \n                           1, 668\u2013676 (2015).","journal-title":"JAMA Oncol."},{"key":"1572_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff, R. M. & Engelhardt, B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. \n                           12, 623\u2013635 (2012).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01572-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:41:29Z","timestamp":1671730889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-01572-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,13]]},"assertion":[{"value":"10 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.C. is an employee of Memgen and inventor on patents and patent applications concerning the composition of matter and use of ISF35 for cancer therapy. W.W.O., M.Si., P.H. and M.J.C. are the authors and inventors on U.S. patent application \u201cMethods and therapeutic combinations for treating tumors\u201d No. 15\/500,618 filed on 31 July 2015, concerning the use of ISF35 for cancer therapy. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1447"}}